Meta Information
ID:bpc-157
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
FDA-Identified Compounding Safety Risk
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
BPC-157 was nominated to be on the FDA's 503A Bulk Drug Substances list (2023) but the nomination was withdrawn. The FDA's advisory states that any compounded drugs containing BPC-157 may present significant safety and immunogenicity risks as well as risks related to impurities in any compounded drugs containing BPC-157. Th FDA compounding advisory applies to all compounded BPC-157 products.
Actionable advice:
BPC-157 has no FDA-approved product and is sold only as a compounded/research peptide with no quality assurance. If you use it, source from a reputable compounding pharmacy and tell your physician.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.
Label source:
FDA bulk drug substances compounding advisory: BPC-157 (Category 2)
Action type:
informational_none
Target id:
/condition/active-cancer
Target name:
Active Cancer
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In vitro and preclinical studies have shown that BPC-157 promotes angiogenesis (the formation of new blood vessels) via upregulation of VEGF and VEGFR2. Angiogenesis is essential for tumor growth and metastasis. Use of BPC-157 in individuals with active or recent malignancy is strongly contraindicated on the basis of this established mechanism.
Actionable advice:
BPC-157 should be avoided during active cancer therapy unless explicitly reviewed and approved by the treating oncology team.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Therefore the angiogenic potential of BPC 157 seems to be closely related to the healing process in vivo with BPC 157 stimulating angiogenesis by up-regulating VEGF expression.
Label source:
Primary literature: Brcic L et al., J Physiol Pharmacol 2009 (PMID 20388964); Primary literature: Hsieh M-J et al., J Mol Med (Berl) 2017 (PMID 27847966)
Action type:
avoid
Target id:
/class/anti-angiogenic-agents
Target name:
Anti-Angiogenic Cancer Drugs (e.g., Bevacizumab, Sorafenib)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
BPC-157 promotes angiogenesis in vitro, which directly opposes the mechanism of anti-angiogenic therapies. Co-administration could render anti-angiogenic cancer drugs less effective at a mechanistic level.
Actionable advice:
It should be avoided completely while on anti-angiogenic cancer therapy.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively.
Label source:
Primary literature: Hsieh M-J et al., J Mol Med (Berl) 2017 (PMID 27847966)
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
There are no known studies of the effect of BPC-157 on fetal development. Its influence on vascular endothelial growth factors and angiogenesis poses a theoretical risk to the developing fetus.
Actionable advice:
This should not be used during pregnancy.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Therefore the angiogenic potential of BPC 157 seems to be closely related to the healing process in vivo with BPC 157 stimulating angiogenesis by up-regulating VEGF expression.
Label source:
Primary literature: Brcic L et al., J Physiol Pharmacol 2009 (PMID 20388964)
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Studies on whether BPC-157 or its metabolites are excreted in breast milk have not been published nor is its effect on a nursing infant known.
Actionable advice:
This should not be used while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Expert review: lactation precaution, no published human data on excretion in breast milk
Action type:
avoid
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In preclinical studies in vivo, BPC-157 has been shown to reduce bleeding time in the presence of the anticoagulant drugs wafarin and heparin.
Actionable advice:
Human safety and efficacy of BPC-157 has not been rigorously studied. The use of BPC-157 and anticoagulants together should be avoided.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
After (tail) amputation, with or without i.v.-heparin or i.g.-warfarin, BPC 157 (10 ?g/kg, 10 ng/kg, i.p., i.v. (heparin), 10 ?g/kg i.g. (warfarin)) always reduced bleeding time and/or haemorrhage and counteracted thrombocytopenia.
Label source:
Primary literature: Stupnisek M et al., PLOS ONE 2015 (PMC4405609)
Action type:
informational_none
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
By modulating the nitric oxide (NO) system, BPC-157 may influence blood pressure. In theory BPC-157 may induce vasoconstriction potentially counteracting the effect of blood pressure-lowering medications.
Actionable advice:
The effect of BPC-157 on blood pressure is not known. Combining BPC-157 with antihypertensive drugs may be unsafe.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
All animals receiving BPC 157 in addition (BPC 157?g+L-NAME; BPC 157?g+L-arginine, BPC 157?g+L-NAME+L-arginine), exhibited decreased haemorrhage and markedly counteracted thrombocytopenia.
Label source:
Primary literature: Stupnisek M et al., PLOS ONE 2015 (PMC4405609)
Action type:
informational_none
Target id:
/class/dopaminergic-agents
Target name:
Dopaminergic Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Preclinical animal studies suggest BPC-157 modulates the dopamine system. In theory this could unpredictably alter the effects of medications for Parkinson's disease, antipsychotics, or stimulants. The evidence is entirely preclinical.
Actionable advice:
It is important to consult a physician before use when taking any medication affecting dopamine.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Thus, a complex protective interaction with both alpha-adrenergic (eg, catecholamine release) and dopaminergic (central) systems could be suggested for both intragastric and intraperitoneal BPC 157 administration. The involvement of beta-receptor stimulation in BPC 157 gastroprotection appears to be related to the route of BPC 157 administration.
Label source:
Primary literature: Sikiric P et al., Dig Dis Sci 1997 (PMID 9073154)
Action type:
informational_none
Target id:
/dietary/meal
Target name:
Any Caloric Meal (Oral BPC-157)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
2
Description:
BPC-157 has demonstrated stability in gastric acid for more than 24 hours per preclinical data, its stability and absorption with food is unknown.
Actionable advice:
BPC-157 oral absorption is likely to be highest in an empty stomach, at least 1 hour before or 2 hours after a meal.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Unlike other growth factors, which need carrier(s) addition, and are rapidly destroyed in human gastric juice, BPC 157 is native and stable in human gastric juice for more than 24 h
Label source:
Primary literature: Seiwerth S et al., Front Pharmacol 2021 (PMC8275860)
Action type:
separate
Target id:
/intervention/tb-500
Target name:
TB-500 (Thymosin Beta-4)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
BPC-157 and TB-500 are often sold together as a combination and are thought to have complementary effects on tissue repair, inflammation reduction, and wound healing through complementary mechanisms (BPC-157 via NO and VEGF; TB-500 via actin binding, cell migration, and angiogenesis). This combination lacks controlled human evidence of safety and efficacy; synergy between these twe peptides is based on mechanism and preclinical data.
Actionable advice:
Tissue repair, anti-inflammatory effect and angiogenesis through different compelmentary mechanisms suggests these two compounds might synergize to promote enhanced healing effects. But there is no evidence of this in clinical or preclinical studies.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
The active segment within TB-500 promotes actin polymerization, progenitor cell recruitment, and enhanced cellular migration—processes integral to wound healing.17,18 Preclinical studies and veterinary use have suggested benefit in tendon and muscle repair, with observed anti-inflammatory effects and proangiogenic activity that mirror those of BPC-157
Label source:
Primary literature: Rahman OF, Lee SJ, Seeds WA, Therapeutic Peptides in Orthopaedics 2026 (PMC12753158)
Action type:
informational_none
Target id:
/class/nsaids
Target name:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Animal studies show BPC-157 can protect against and help repair NSAID-induced gastrointestinal damage, acting as a cytoprotective agent on the gastric mucosa. This is a preclinical observation with no controlled human data.
Actionable advice:
May be co-administered to potentially mitigate gastric side effects of NSAIDs, based on preclinical data. No human trial evidence for this specific combination exists.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The arguments for BPC 157 antidote activity (i.e., the role of BPC 157 in cytoprotection, being a novel mediator of Robert's cytoprotection and BPC 157 beneficial effects on NSAIDs mediated lesions in the gastrointestinal tract, liver and brain and finally, counteraction of aspirin-induced prolonged bleeding and thrombocytopenia) obviously have a counteracting effect on several established side-effects of NSAIDs use.
Label source:
Primary literature: Sikiric P et al., Curr Pharm Des 2013 (PMID 22950504)
Action type:
informational_none
Target id:
/class/serotonergic-agents
Target name:
Serotonergic Medications (SSRIs, SNRIs)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Preclinical data suggests a potential influence on the serotonin system, which could theoretically alter the effects or side effects of serotonergic drugs. This interaction is speculative and based on animal data only.
Actionable advice:
Consulting a physician and watching for any mood or behavioral changes may help when taking serotonergic medications.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Thereby, in severe serotonin syndrome, gastric pentadecapeptide BPC 157 (alone, no behavioral or temperature effect) has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena.
Label source:
Primary literature: Boban Blagaic A et al., Eur J Pharmacol 2005 (PMID 15840402)
Action type:
monitor
Target id:
/class/chemotherapy-radiation
Target name:
Anti-Angiogenic Cancer Drugs
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 promotes angiogenesis in vitro, which directly opposes the mechanism of anti-angiogenic therapies (e.g., bevacizumab, sorafenib) and could render them less effective. There are no published reports on the effect of BPC-157 on other chemotherapies.
Actionable advice:
BPC-157 should be avoided during active cancer therapy unless explicitly reviewed and approved by the treating oncology team.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively.
Label source:
Primary literature: Hsieh M-J et al., J Mol Med (Berl) 2017 (PMID 27847966)
Action type:
avoid
Target id:
/class/ghrps-ghrhs
Target name:
Growth Hormone Secretagogues (e.g., Ipamorelin, CJC-1295)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 may upregulate growth hormone receptors in tissues, potentially enhancing the tissue-repair signaling and effects of peptides that increase growth hormone release.
Actionable advice:
May be used concurrently for a potentially synergistic effect on recovery and healing.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively.
Label source:
Primary literature: Hsieh M-J et al., J Mol Med (Berl) 2017 (PMID 27847966)
Action type:
informational_none
Target id:
/class/proton-pump-inhibitors
Target name:
Proton Pump Inhibitors (PPIs)
Severity:
minor
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
BPC-157 has been tested together with omeprazole a proton pump inhibitor in a preclinical model. No effect of omerprazole on the stability of BPC-157 was reported.
Actionable advice:
Any change in stability of BPC-157 due to proton pump inhibitor drugs is unknown.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Furthermore, unlike H2-blockers and omeprazole, BPC 157 stimulates the formation of granulation tissue, suggesting a particular activity, similar to that previously noted for sucralfate.
Label source:
Primary literature: Sikiric P et al., J Physiol Paris 1999 (PMID 10672992)
Action type:
informational_none